biote Corp. (BTMD)
Nasdaq · Healthcare · Medical Care Facilities
$1.12−2.61%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $38.0M
- P/E (trailing)
- 8.0
- Forward P/E
- 2.5
- 52-week range
- $1.10 – $3.26
- 52-week change
- −59.51%
- EPS (trailing)
- $0.14
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $192M (−2.52%)
- Net income
- $27.0M
- Operating margin
- 18.5%
- Diluted EPS
- $0.74
- Free cash flow
- $30.2M
From the company’s annual report on SEC EDGAR.
About biote Corp.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Headquarters: Irving, United States · 223 employees · biote.com